Krishna Teja Ravivarapu
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Krishna Teja Ravivarapu has a total of 49 co-authors. Here are the top co-authors by number of shared publications:
- Michael A. Palese
Department of Urology, Icahn School of Medicine at Mount Sinai, New York, NY, USA
3 shared publications Alexander C. Small
Department of Urology, Montefiore Medical Center and Albert Einstein College of Medicine, Bronx, New York, USA
2 shared publications- Evan B. Garden
Department of Urology, Icahn School of Medicine at Mount Sinai, New York, New York
2 shared publications Joseph Sewell Araya
Department of Urology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
2 shared publications- Laura A. Smith Callahan
The Vivian L Smith Department of Neurosurgery, McGovern Medical School at University of Texas Health Science Center at Houston, Houston, Texas, 77030
2 shared publications Micah Levy
Department of Urology, Icahn School of Medicine at Mount Sinai, New York, New York, USA
2 shared publications
Latest Publications
- 1 February 2024
- Published by SAGE Publications in Journal of Endourology
- Vol. 38 (2) , 136-141
Comparison of Single-Port Robotic Donor Nephrectomy and Laparoscopic Donor Nephrectomy
Purpose: To compare the intra-operative and post-operative outcomes of Single-Port Robotic Donor Nephrectomies (SP RDNs) and Laparoscopic Donor Nephrectomies (LDNs) Materials and Methods: We retrospectively reviewed our institutional database for patients who received LDN or SP RDN between September 2020 and December 2022. Donor baseline characteristics, intra-operative outcomes, post-operative outcomes, and recipient renal function were extracted and compared between LDN and SP RDN. SP RDN learning curve analysis based on operative time and graft extraction time was performed using Cumulative Sum Analysis. Results: 144 patients underwent LDN and 32 patients underwent SP RDN. LDN and SP RDN had similar operative times (LDN: 190.3 ± 28.0 min., SP RDN: 194.5 ± 35.1 min., p=0.3253). SP RDN patients had significantly greater extraction times (LDN: 83.2 ± 40.3 sec., SP RDN: 204.1 ± 52.2 sec, p<0.0001) and warm ischemia times (LDN: 145.1 ± 61.7 sec., SP RDN: 275.4 ± 65.6 sec., p<0.0001). There were no differences in patient subjective pain scores, inpatient opioid usage, or Clavien-Dindo II+ complications. Short- and medium-term post-operative donor and recipient renal function were also similar between the groups. SP RDN graft extraction time and total operative time learning curves were achieved at case 27 and 13, respectively. Conclusion: SP RDN is a safe and feasible alternative to LDN that minimizes post-operative abdominal incisional scars and has a short learning curve. Future randomized prospective clinical trials are needed to confirm the findings of this study and to identify other potential benefits and drawbacks of SP RDNs.
- 1 February 2024
- Published by SAGE Publications in Journal of Endourology
- Vol. 38 (2) , 136-141
Comparison of Single-Port Robotic Donor Nephrectomy and Laparoscopic Donor Nephrectomy
Purpose: To compare the intra-operative and post-operative outcomes of Single-Port Robotic Donor Nephrectomies (SP RDNs) and Laparoscopic Donor Nephrectomies (LDNs) Materials and Methods: We retrospectively reviewed our institutional database for patients who received LDN or SP RDN between September 2020 and December 2022. Donor baseline characteristics, intra-operative outcomes, post-operative outcomes, and recipient renal function were extracted and compared between LDN and SP RDN. SP RDN learning curve analysis based on operative time and graft extraction time was performed using Cumulative Sum Analysis. Results: 144 patients underwent LDN and 32 patients underwent SP RDN. LDN and SP RDN had similar operative times (LDN: 190.3 ± 28.0 min., SP RDN: 194.5 ± 35.1 min., p=0.3253). SP RDN patients had significantly greater extraction times (LDN: 83.2 ± 40.3 sec., SP RDN: 204.1 ± 52.2 sec, p<0.0001) and warm ischemia times (LDN: 145.1 ± 61.7 sec., SP RDN: 275.4 ± 65.6 sec., p<0.0001). There were no differences in patient subjective pain scores, inpatient opioid usage, or Clavien-Dindo II+ complications. Short- and medium-term post-operative donor and recipient renal function were also similar between the groups. SP RDN graft extraction time and total operative time learning curves were achieved at case 27 and 13, respectively. Conclusion: SP RDN is a safe and feasible alternative to LDN that minimizes post-operative abdominal incisional scars and has a short learning curve. Future randomized prospective clinical trials are needed to confirm the findings of this study and to identify other potential benefits and drawbacks of SP RDNs.
- 1 December 2022
- Published by SAGE Publications in Journal of Endourology
- Vol. 36 (12) , 1559-1566
Medium-Term Real-World Outcomes of Minimally Invasive Surgical Therapies for Benign Prostatic Hyperplasia: Water Vapor Thermal Therapy (Rezum) vs Prostatic Urethral Lift (UroLift) in a High-Volume Urban Academic Center
Purpose: Water Vapor Thermal Therapy (WVTT, i.e. Rezum®) and Prostatic Urethral Lift (PUL, i.e. Urolift®) are minimally invasive surgical therapy (MIST) options for benign prostatic hyperplasia (BPH). Few studies have directly compared the two procedures. We examined the clinical characteristics and postoperative outcomes of patients undergoing WVTT and PUL at our high-volume urban academic center. Method: We reviewed our institutional MIST database to identify patients with prostate sizes ≥30 and ≤80 cc who underwent WVTT or PUL for treatment of BPH between January 2017 and September 2021. Pre- and post-operative outcomes including retreatment rates, AUA symptom score (AUA-SS), maximum flow (Qmax), post-void residual (PVR), medication usage, trial of void success rates, catheterization requirements, and postoperative complications within 90 days were extracted and compared between procedures. Results: 307 patients received WVTT and 110 patients received PUL with average follow-up times of 11.3 and 12.8 months, respectively. WVTT patients showed significant improvements in AUA-SS, Qmax, and PVR, whereas PUL patients showed improvements in only AUA-SS and Qmax. Both WVTT and PUL patients with longitudinal follow-up demonstrated improvements in AUA-SS, Qmax, and PVR. Postoperatively, alpha-blocker utilization was significantly decreased following both WVTT and PUL (WVTT: 73.9% to 46.6%, PUL: 76.4% to 38.2%, both p<0.001). Compared to patients receiving PUL, WVTT patients more frequently reported postoperative dysuria (22.8% vs 8.3%, p=0.001) and non-clot-related retention (18.9% vs 7.3%, p=0.005); PUL patients more frequently experienced postoperative clot retention (7.3% vs 2.6%, p=0.027). There were no differences in rates of postoperative bladder spasm, TOV success, urinary tract infections, or emergency department visits. Postoperative erectile dysfunction and retrograde ejaculation were rare and occurred at similar rates. Conclusion: In the real-world setting, WVTT and PUL have similar medium-term efficacy in improving symptoms and decreasing medication utilization for patients with BPH. Differences in postoperative complication profiles should inform patient counseling.
- 1 December 2022
- Published by SAGE Publications in Journal of Endourology
- Vol. 36 (12) , 1559-1566
Medium-Term Real-World Outcomes of Minimally Invasive Surgical Therapies for Benign Prostatic Hyperplasia: Water Vapor Thermal Therapy (Rezum) vs Prostatic Urethral Lift (UroLift) in a High-Volume Urban Academic Center
Purpose: Water Vapor Thermal Therapy (WVTT, i.e. Rezum®) and Prostatic Urethral Lift (PUL, i.e. Urolift®) are minimally invasive surgical therapy (MIST) options for benign prostatic hyperplasia (BPH). Few studies have directly compared the two procedures. We examined the clinical characteristics and postoperative outcomes of patients undergoing WVTT and PUL at our high-volume urban academic center. Method: We reviewed our institutional MIST database to identify patients with prostate sizes ≥30 and ≤80 cc who underwent WVTT or PUL for treatment of BPH between January 2017 and September 2021. Pre- and post-operative outcomes including retreatment rates, AUA symptom score (AUA-SS), maximum flow (Qmax), post-void residual (PVR), medication usage, trial of void success rates, catheterization requirements, and postoperative complications within 90 days were extracted and compared between procedures. Results: 307 patients received WVTT and 110 patients received PUL with average follow-up times of 11.3 and 12.8 months, respectively. WVTT patients showed significant improvements in AUA-SS, Qmax, and PVR, whereas PUL patients showed improvements in only AUA-SS and Qmax. Both WVTT and PUL patients with longitudinal follow-up demonstrated improvements in AUA-SS, Qmax, and PVR. Postoperatively, alpha-blocker utilization was significantly decreased following both WVTT and PUL (WVTT: 73.9% to 46.6%, PUL: 76.4% to 38.2%, both p<0.001). Compared to patients receiving PUL, WVTT patients more frequently reported postoperative dysuria (22.8% vs 8.3%, p=0.001) and non-clot-related retention (18.9% vs 7.3%, p=0.005); PUL patients more frequently experienced postoperative clot retention (7.3% vs 2.6%, p=0.027). There were no differences in rates of postoperative bladder spasm, TOV success, urinary tract infections, or emergency department visits. Postoperative erectile dysfunction and retrograde ejaculation were rare and occurred at similar rates. Conclusion: In the real-world setting, WVTT and PUL have similar medium-term efficacy in improving symptoms and decreasing medication utilization for patients with BPH. Differences in postoperative complication profiles should inform patient counseling.
- 26 November 2021
- Published by Elsevier in The American Journal of Surgery
- Vol. 223 (6) , 1120-1125
Adrenalectomy outcomes predicted by a 5-item frailty index (5-iFI) in the ACS-NSQIP database
- 26 November 2021
- Published by Elsevier in The American Journal of Surgery
- Vol. 223 (6) , 1120-1125
Adrenalectomy outcomes predicted by a 5-item frailty index (5-iFI) in the ACS-NSQIP database
- 1 April 2018
- Published by Elsevier in Acta Biomaterialia
- Vol. 71, 271-278
Mechanical stabilization of proteolytically degradable polyethylene glycol dimethacrylate hydrogels through peptide interaction
- 1 April 2018
- Published by Elsevier in Acta Biomaterialia
- Vol. 71, 271-278
Mechanical stabilization of proteolytically degradable polyethylene glycol dimethacrylate hydrogels through peptide interaction
- 18 April 2017
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 3 (5) , 776-781
Human Induced Pluripotent Stem Cell Derived Neural Stem Cell Survival and Neural Differentiation on Polyethylene Glycol Dimethacrylate Hydrogels Containing a Continuous Concentration Gradient of N-Cadherin Derived Peptide His-Ala-Val-Asp-Ile
Although preclinical models of spinal cord injury have shown that matrix inclusion in stem cell therapy leads to greater neurological improvements than that including cells alone, there has been insufficient matrix optimization for human cells. N-Cadherin influences the development and maintenance of neural tissue, but the effects of N-cadherin derived peptide His-Ala-Val-Asp-Ile (HAVDI) on the survival, neurite extension, and expression of neural differentiation markers in human induced pluripotent stem cell derived neural stems (hNSC) have not been widely examined. Using polyethylene glycol hydrogels containing a continuous gradient of HAVDI, this study identifies concentration dependent effects on hNSC survival and neural differentiation.
- 18 April 2017
- Published by American Chemical Society (ACS) in ACS Biomaterials Science & Engineering
- Vol. 3 (5) , 776-781
Human Induced Pluripotent Stem Cell Derived Neural Stem Cell Survival and Neural Differentiation on Polyethylene Glycol Dimethacrylate Hydrogels Containing a Continuous Concentration Gradient of N-Cadherin Derived Peptide His-Ala-Val-Asp-Ile
Although preclinical models of spinal cord injury have shown that matrix inclusion in stem cell therapy leads to greater neurological improvements than that including cells alone, there has been insufficient matrix optimization for human cells. N-Cadherin influences the development and maintenance of neural tissue, but the effects of N-cadherin derived peptide His-Ala-Val-Asp-Ile (HAVDI) on the survival, neurite extension, and expression of neural differentiation markers in human induced pluripotent stem cell derived neural stems (hNSC) have not been widely examined. Using polyethylene glycol hydrogels containing a continuous gradient of HAVDI, this study identifies concentration dependent effects on hNSC survival and neural differentiation.